Postmenopausale Hormontherapie und Mammakarzinom

Armamento-Villareal R, Civitelli R(1995) Estrogen action on the bone mass of postmenopausal women is dependent on body mass and initial bone density. J Clin Endocrinol Metab 80: 776–782

Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293–297

Bluming AZ (1993) Hormone replacement therapy: benefits and risks for the general postmenopausal female population and for women with a history of previously treated breast cancer. Semin Oncol 20: 662–674

Chen CL, Weiss NS, Newcomb P, Barlow W, White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287: 734–741

Col NF, Hirota LK, Orr RK,. Erban JK, Wong JB, Joseph Lau J (2001) Hormone Replacement Therapy After Breast Cancer: A Systematic Review and Quantitative Assessment of Risk. J Clin Oncol 19: 2357–2363

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 (9084): 1047–1059

Colditz GA, Egan KM, Stampfer MJ (1993) Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 168: 1473–1480

Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ,Hennekens C, Rosner B, Speizer F (1995 ) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med.332 (24): 1589–1593

Colditz GA (1998) Relationship between estrogen levels, use of hormon replacement therapy, and breast cancer. J Natl Cancer Inst 90: 814–23

Delgado RC, Lubian-Lopez DM (2001) Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 38: 147–156

Di Saia PJ, Brewster WR (2000) Hormone replacement therapy in breast cancer survivors. Am J Obstet Gynecol 183: 517

Di Saia PJ, Odicino F, Grosen EA, Cowan B, Pecorelli S, Wile AG (1993) Hormone replacement therapy in breast cancer. Lancet 342: 1232

Di Saia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H (1996) Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 174: 1494–1498

Dupont WD, Page DL (1991 ) Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151 (1): 67–72

Eden J (1995) Should women who have had breast cancer take hormone replacement therapy? Maturitas 22: 69–70

Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr (1996) Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87: 6–12

Gajdos C, Tartter PI, Babinszki A (2000) Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol 95: 513–518

Gambrell RD Jr, Maier RC, Sanders BI (1983) Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 62: 435–443

Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA281: 2091–2097

Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E (1999) Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 130: 262–269

Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE (1995) Reproducibility of plasma hormone levels in postmenopausal women over a 2–3-year period. Cancer Epidemiol Biomarkers Prev 4: 649–654

Heine JJ, Malhotra P (2002) Mammographic tissue, breast cancer risk, serial image analysis, and digital mammography. Part 1. Tissue and related risk factors. Acad Radiol 9 (3): 298–316

Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84: 4559–4565

Hulley S, Furberg C, Barrett-Connor E et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 288: 58–66

Kavanagh AM, Mitchell H, Giles GG ( 2000) Hormone replacement therapy and accuracy of mammographic screening. Lancet 355: 270–274

Laidlaw IJ, Clarke RB, Howell A, Owen AW, Potten CS, Anderson E (1995) The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 136: 164–171

Li CI, Weiss NS, Stanford JL, Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88: 2570–2577

Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Soderqvist G,Mol-Arts M, Barkfeldt J, von Schoultz B (2002) Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 186 (4): 717–722

Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81: 339–344

Marchbanks PA, McDonald JA, Wilson HG et al. (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346: 2025–2032

Musgrove EA, Sutherland RL (1994) Cell cycle control by steroid hormones. Semin Cancer Biol 5: 381–9

Nanda K, Bastian LA, Schulz K (2002) Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 186 (2): 325–334

Pike MC, Spicer DV (1993) The chemoprevention of breast cancer by reducing sex steroid exposure: perspectives from epidemiology. J Cell Biochem (Suppl) 17G 26–36

Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. (1997) Estrogen-Progestin Replacement Therapy and Endometrial Cancer. J Nat Cancer Inst 89: 1110–1116

Poutanen M, Isomaa V, Peltoketo H, Vihko R (1995) Regulation of oestrogen action: role of 17 beta-hydroxysteroid dehydrogenases. Ann Med 27: 675–682

Powles TJ, Hickish T, Casey S, O'Brien M (1993) Hormone replacement after breast cancer. Lancet 342: 60–61

Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE (1990) Increased cell division as a cause of human cancer. Cancer Res 50: 7415–7421

Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen vs. estrogen plus progestin. J Natl Cancer Inst 92: 328–332

Sala E, Warren R, McCann J, Duffy S, Luben R, Day N (2000) High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study. Int J Epidemiol 29: 629–636

Salmon RJ, Ansquer Y, Asselain B, Languille O, Lesec G, Remvikos Y (1999) Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause. Oncol Rep 6: 699–703

Schairer C, Gail M, Byrne C et al. (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91: 264–270

Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R (1992) Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 79: 286–294

Steinberg KK, Smith SJ, Thacker SB, Stroup DF (1994) Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 5: 415–421

Stoll BA, Parbhoo S (1988) Treatment of menopausal symptoms in breast cancer patients. Lancet 337: 1278–1279

The Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94 (8): 606–616

Thomas HV, Reeves GK, Key TJ (1997) Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 6: 922–928

Vassilopoulou-Selin R, Asmar L, Hortobagyi GN et al. (1999) Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 5: 1482–1487

Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN et al. (2002) Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 95: 1817–1826

Wile AG, Opfell RW, Margileth DA (1993) Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 165: 372–375

Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD (1995) Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study. Cancer 76: 275–283